The end of the 30-month Hatch-Waxman stay does not constitute an FDA action date or even a rough indication of when the FDA will rule on the Copaxone ANDA.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”